A share price of ARS Pharmaceuticals Inc [SPRY] is currently trading at $14.53, up 1.11%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The SPRY shares have gain 7.23% over the last week, with a monthly amount drifted -4.22%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Raymond James upgraded its rating to Strong Buy on August 13, 2024, and elevated its price target to $22. On August 12, 2024, Leerink Partners reiterated its Outperform rating and revised its price target to $20 on the stock. Raymond James started tracking the stock assigning a Outperform rating and suggested a price target of $18 on July 25, 2024. Leerink Partners upgraded its rating to a Outperform and raised its price target to $18 on March 05, 2024. William Blair upgraded its rating to Outperform for this stock on February 20, 2024. In a note dated September 20, 2023, William Blair downgraded an Mkt Perform rating on this stock.
ARS Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $4.65 and $18.51. Currently, Wall Street analysts expect the stock to reach $23.33 within the next 12 months. ARS Pharmaceuticals Inc [NASDAQ: SPRY] shares were valued at $14.53 at the most recent close of the market. An investor can expect a potential return of 60.56% based on the average SPRY price forecast.
Analyzing the SPRY fundamentals
Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -23.84%, Pretax Profit Margin comes in at -19.35%, and Net Profit Margin reading is -19.35%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.23 and Total Capital is -0.3.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.16 points at the first support level, and at 13.80 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.90, and for the 2nd resistance point, it is at 15.27.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ARS Pharmaceuticals Inc [NASDAQ:SPRY] is 12.54. As well, the Quick Ratio is 12.50, while the Cash Ratio is 2.39. Considering the valuation of this stock, the price to sales ratio is 555.57, the price to book ratio is 7.02.
Transactions by insiders
Recent insider trading involved Chakma Justin, Chief Business Officer, that happened on Nov 26 ’24 when 42186.0 shares were sold. Chief Business Officer, Chakma Justin completed a deal on Nov 25 ’24 to sell 32814.0 shares. Meanwhile, Chief Business Officer Chakma Justin sold 25000.0 shares on Nov 27 ’24.
